The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Tissue-resident memory T cells in breast cancer control and immunotherapy responses

(2020) Ann Byrne et al.   Nature Reviews Clinical Oncology

Moving towards personalized treatments of immune-related adverse events

(2020) Khashayar Esfahani et al.   Nature Reviews Clinical Oncology

Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer

(2020) Vida Vafaizadeh et al.   Frontiers in Cell and Developmental Biology

PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer

(2020) Haiying Zhu et al.   DRUG DISCOVERY TODAY

Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care

(2020) Sima Singh et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

(2019) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

(2019) Ramon Colomer et al.   ONCOLOGIST

Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

(2019) Nina D’Abreo et al.   Nature Reviews Clinical Oncology

Tissue-Resident Memory T Cells in Cancer Immunosurveillance

(2019) Simone L. Park et al.   TRENDS IN IMMUNOLOGY

Immune checkpoint inhibitors: a promising anticancer therapy

(2019) Sima Singh et al.   DRUG DISCOVERY TODAY

The breast tumor microenvironment: role in cancer development, progression and response to therapy

(2018) Suruchi Mittal et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

(2018) Peter Savas et al.   NATURE MEDICINE

Triple-negative breast cancers — a panoply of cancer types

(2018) Fresia Pareja et al.   Nature Reviews Clinical Oncology

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

(2018) Natalie J. Neubert et al.   Science Translational Medicine

Nanoscale delivery systems for cancer immunotherapy

(2018) Zejun Wang et al.   Materials Horizons

Putting the Immunologic Brakes on Cancer

(2018) Jedd Wolchok   CELL

Targeting triple negative breast cancer with histone deacetylase inhibitors

(2017) Palma Fedele et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer

(2016) Jacqueline Tsai et al.   ANNALS OF SURGICAL ONCOLOGY

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

(2016) Claire F. Friedman et al.   Current Oncology Reports

Immune cell quantitation in normal breast tissue lobules with and without lobulitis

(2014) Amy C. Degnim et al.   BREAST CANCER RESEARCH AND TREATMENT

Tissue-Resident Memory T Cells

(2014) Jason M. Schenkel et al.   IMMUNITY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Molecular regulation of effector and memory T cell differentiation

(2014) John T Chang et al.   NATURE IMMUNOLOGY

Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario

(2014) M. Bonotto et al.   ONCOLOGIST

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Leukocyte composition of human breast cancer

(2011) B. Ruffell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease

(2010) W. Miehsler et al.   Journal of Crohns & Colitis

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrins

(2009) Malgorzata Barczyk et al.   CELL AND TISSUE RESEARCH